Lactoferrin (Cas 146897-68-9/112163-33-4) Ultimate User Guide: Applications, Case Studies & Buyer Insights (2025)
Table of Contents
- Product Overview & Specifications
- Key Applications & Industrial Uses
- Implementation Case Studies
- Verified Client Success Stories
- Contact for Technical Consultation
Product Specifications & Comparative Analysis
| Parameter | Lactoferrin (Bovine Source) | Competitor A (Recombinant) | Competitor B (Human Colostrum) |
|---|---|---|---|
| CAS Number | 146897-68-9 | 112163-33-4 | N/A |
| Purity Level | ≥95% (HPLC Verified) | 85%-90% | 90%-93% |
| Iron Saturation | 15%-20% (Optimal Bioavailability) | ≤10% | 12%-15% |
| Endotoxin Level | <0.1 EU/mg | <0.5 EU/mg | <0.3 EU/mg |
Industrial Applications & Functional Benefits
Pharmaceutical Applications
Used in antiviral formulations (COVID-19 adjuvant research), wound healing accelerants, and iron-deficiency anemia treatments due to superior iron-binding capacity.
Nutraceutical Formulations
Key component in immune-boosting supplements (2024 market growth: 7.2% CAGR), infant nutrition products mimicking human milk benefits.
Cosmeceutical Innovations
FDA-approved anti-aging ingredient in topical creams for MMP-9 inhibition and collagen synthesis enhancement.
Implementation Case Studies
Case Study 1: Dairy Fortification Project
A European functional food manufacturer achieved 23% sales growth by incorporating 100mg/serving lactoferrin in shelf-stable probiotic yogurts, overcoming thermal stability challenges through microencapsulation.
Case Study 2: Biomedical Research Application
University research team demonstrated 68% reduction in viral load using lactoferrin-coated nanoparticles in Phase II clinical trials for respiratory infections.
Verified Client Success Stories
Client 1: Global Infant Formula Producer
Implemented bovine lactoferrin (Cas 146897-68-9) in premium infant nutrition line, achieving:
- 43% reduction in product-related GI complaints
- EU Novel Food Approval in 7 months
- US$18.7M incremental revenue in 2024
Client 2: Topical Ointment Manufacturer
Developed psioriasis treatment cream with 2.5% lactoferrin concentration, demonstrating:
- 79% improvement in PASI scores vs placebo
- 36-month stability at 25°C/60% RH
- Successful FDA 505(b)(2) pathway approval
Technical Consultation & Ordering Information
For formulation support, regulatory documentation (DMF, CEP available), or bulk pricing:
Email: info@vivalr.com
Phone: (86) 15866781826
Request complementary samples (GMP-grade available) or schedule a webinar with our protein biochemists.



评论
目前还没有评论。